Definium Therapeutics, Inc.
DFTX
Kedudukan dalam Saham
#3606
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Harga Saham
$35.22
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$4.73B
Perubahan (1 hari)
6.82%
Perubahan (1 tahun)
222.07%
Negara
US
Perdagangan Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Nisbah P/B bagi Definium Therapeutics, Inc. (DFTX)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Definium Therapeutics, Inc., nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Definium Therapeutics, Inc. dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
